Mankind Pharma Ltd

Mankind Pharma Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Mankind Pharma Ltd

₹ 2,576 -0.65%
30 Jul - close price
mankindpharma.com BSE: 543904 NSE: MANKIND
About

Incorporated in 1995, Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations in various acute and chronic therapeutic areas and several consumer healthcare products.[1]

Key Points

Leadership[1]
- #1 Rank in Prescriptions over the last 8 yrs.
- #2 Rank by volume & #4 Rank by value in IPM
- 4 Consumer healthcare brands ranked #1 in their categories.

Website BSE NSE
  • Market Cap ₹ 1,06,384 Cr.
  • Current Price ₹ 2,576
  • High / Low ₹ 2,674 / 1,910
  • Stock P/E 49.9
  • Book Value ₹ 395
  • Dividend Yield 0.04 %
  • ROCE 13.5 %
  • ROE 13.1 %
  • Face Value ₹ 1.00
Edit ratios

Pros

  • Company has reduced debt.

Cons

  • Promoter holding has decreased over last 3 years: -3.87%

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE 500 BSE Healthcare BSE 200 BSE Dollex 200 Nifty 500

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
2,579 2,708 2,607 2,422 2,868 3,061 3,199 3,079 3,570 3,697 3,567 3,443 4,031
1,924 2,025 2,000 1,836 2,196 2,214 2,383 2,396 2,724 2,776 2,648 2,513 2,974
Operating Profit 655 683 606 586 672 847 816 683 847 921 919 930 1,056
OPM % 25% 25% 23% 24% 23% 28% 26% 22% 24% 25% 26% 27% 26%
63 63 75 94 108 109 87 249 83 94 -31 94 49
Interest 6 9 9 9 11 7 221 191 171 170 157 142 110
Depreciation 87 96 110 100 103 100 187 231 219 222 223 223 226
Profit before tax 624 641 562 572 666 849 495 511 540 624 509 659 769
Tax % 21% 20% 18% 17% 18% 22% 22% 17% 18% 17% 19% 15% 25%
494 511 460 477 543 659 385 425 445 520 414 559 574
EPS in Rs 12.15 12.51 11.33 11.76 13.39 16.31 9.22 10.20 10.62 12.39 9.90 13.43 13.75
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
3,334 5,865 6,214 7,782 8,749 10,260 12,207 14,278 14,738
2,748 4,427 4,565 5,791 6,848 7,743 9,182 10,653 10,911
Operating Profit 586 1,438 1,649 1,991 1,902 2,517 3,026 3,625 3,827
OPM % 18% 25% 27% 26% 22% 25% 25% 25% 26%
76 122 183 210 141 295 548 238 207
Interest 2 23 21 60 46 34 432 644 579
Depreciation 39 99 119 167 326 378 621 886 893
Profit before tax 621 1,438 1,692 1,975 1,671 2,399 2,521 2,333 2,562
Tax % 29% 27% 24% 26% 22% 19% 20% 17%
445 1,056 1,293 1,453 1,310 1,942 2,011 1,938 2,068
EPS in Rs 219.33 25.72 31.59 35.78 32.00 47.75 48.26 46.34 49.47
Dividend Payout % 0% 0% 24% 0% 0% 0% 0% 2%
Compounded Sales Growth
10 Years: %
5 Years: 18%
3 Years: 18%
TTM: 14%
Compounded Profit Growth
10 Years: %
5 Years: 11%
3 Years: 17%
TTM: 13%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: 13%
1 Year: 0%
Return on Equity
10 Years: %
5 Years: 17%
3 Years: 16%
Last Year: 13%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 20 40 40 40 40 40 41 41
Reserves 2,035 3,445 4,682 6,115 7,395 9,323 14,291 16,259
0 131 241 873 170 207 8,511 6,312
968 1,449 1,397 2,080 2,080 2,313 4,808 5,143
Total Liabilities 3,022 5,065 6,360 9,108 9,686 11,883 27,652 27,755
316 1,600 1,664 3,588 4,251 4,545 19,005 18,620
CWIP 47 317 372 701 550 282 826 1,128
Investments 959 829 1,512 1,109 1,346 2,568 2,042 1,985
1,700 2,319 2,811 3,709 3,538 4,488 5,780 6,022
Total Assets 3,022 5,065 6,360 9,108 9,686 11,883 27,652 27,755

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
1,070 1,137 920 1,813 2,152 2,413 3,121
-436 -1,222 -1,369 -1,052 -2,081 -12,624 -181
-531 -8 605 -740 5 10,233 -2,953
Net Cash Flow 103 -92 156 22 77 22 -12
Free Cash Flow 853 826 -1,423 987 1,771 1,895 2,387
CFO/OP 97% 96% 71% 112% 103% 98% 102%

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 22 33 19 18 24 30 46 44
Inventory Days 166 175 243 265 188 180 219 193
Days Payable 71 145 137 162 126 90 119 121
Cash Conversion Cycle 117 63 125 121 86 120 146 117
Working Capital Days 56 30 32 24 39 53 -28 -40
ROCE % 37% 32% 22% 26% 17% 14%

Insights

In beta
Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Chronic Share in Total Portfolio
%

Log in to view insights

Please log in to see hidden values.

Login
CVM (Covered Market) Share in Total IPM
%
Market Share by Value in IPM
%
Volume Share in IPM
%
Brand Families >INR 100 Cr
count
Field Force Size
count
Volume Growth
%
R&D Expenditure (Percentage of Turnover)
% ・Standalone data

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
76.50% 76.50% 74.88% 74.87% 74.87% 72.71% 72.70% 72.67% 72.67% 72.66% 72.66% 72.63%
4.18% 6.74% 9.87% 11.58% 12.37% 13.34% 12.92% 13.07% 12.83% 11.34% 10.24% 9.45%
4.56% 9.78% 11.14% 9.94% 9.91% 11.05% 11.47% 11.50% 11.91% 13.26% 14.46% 15.39%
14.76% 6.97% 4.10% 3.61% 2.86% 2.89% 2.89% 2.75% 2.57% 2.75% 2.63% 2.53%
No. of Shareholders 1,34,7311,27,4491,35,1161,53,4501,63,8541,71,2811,80,5971,79,5491,70,3471,77,5391,77,6061,66,715

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings

Concalls